IOVANCE BIOTHERAPEUTICS, INC.

(IOVA)
  Report
Delayed Nasdaq  -  04:00 2022-07-05 pm EDT
11.57 USD   +0.87%
07/01Goldman Sachs Adjusts Iovance Biotherapeutics' Price Target to $18 From $64, Maintains Buy Rating
MT
06/24IOVANCE BIOTHERAPEUTICS, INC.(NASDAQGM : IOVA) added to Russell 2000 Index
CI
06/24IOVANCE BIOTHERAPEUTICS, INC.(NASDAQGM : IOVA) added to Russell 2000 Value Index
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/28/2022 06/29/2022 06/30/2022 07/01/2022 07/05/2022 Date
10.98(c) 10.89(c) 11.04(c) 11.47(c) 11.57(c) Last
5 130 356 3 450 186 3 322 135 4 141 693 4 493 235 Volume
-1.35% -0.82% +1.38% +3.89% +0.87% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -393 M - -
Net cash position 2022 222 M - -
P/E ratio 2022 -4,71x
Yield 2022 -
Sales 2023 65,3 M - -
Net income 2023 -374 M - -
Net cash position 2023 165 M - -
P/E ratio 2023 -5,20x
Yield 2023 -
Capitalization 1 818 M 1 818 M -
EV / Sales 2022 -
EV / Sales 2023 25,3x
Nbr of Employees 319
Free-Float 91,8%
More Financials
Company
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cell therapies as cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. It has developed a new, shorter manufacturing process for tumor infiltrating lymphocyte (TIL) known as Generation 2 (Gen 2), which... 
More about the company
Ratings of Iovance Biotherapeutics, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
D+
More Ratings
All news about IOVANCE BIOTHERAPEUTICS, INC.
07/01Goldman Sachs Adjusts Iovance Biotherapeutics' Price Target to $18 From $64, Maintains ..
MT
06/24IOVANCE BIOTHERAPEUTICS, INC.(NASDAQ : IOVA) added to Russell 2000 Index
CI
06/24IOVANCE BIOTHERAPEUTICS, INC.(NASDAQ : IOVA) added to Russell 2000 Value Index
CI
06/24IOVANCE BIOTHERAPEUTICS, INC.(NASDAQ : IOVA) dropped from Russell 1000 Dynamic Index
CI
06/24IOVANCE BIOTHERAPEUTICS, INC.(NASDAQ : IOVA) dropped from Russell 3000 Growth Index
CI
06/24IOVANCE BIOTHERAPEUTICS, INC.(NASDAQ : IOVA) dropped from Russell 1000 Value Index
CI
06/24IOVANCE BIOTHERAPEUTICS, INC.(NASDAQ : IOVA) dropped from Russell 1000 Growth Index
CI
06/24IOVANCE BIOTHERAPEUTICS, INC.(NASDAQ : IOVA) added to Russell 2000 Dynamic Index
CI
06/24IOVANCE BIOTHERAPEUTICS, INC.(NASDAQ : IOVA) dropped from Russell 1000 Index
CI
06/24IOVANCE BIOTHERAPEUTICS, INC.(NASDAQ : IOVA) dropped from Russell Midcap Index
CI
06/24IOVANCE BIOTHERAPEUTICS, INC.(NASDAQ : IOVA) dropped from Russell Small Cap Comp Growth In..
CI
06/24IOVANCE BIOTHERAPEUTICS, INC.(NASDAQ : IOVA) dropped from Russell 3000E Growth Index
CI
06/24IOVANCE BIOTHERAPEUTICS, INC.(NASDAQ : IOVA) dropped from Russell Midcap Value Index
CI
06/24IOVANCE BIOTHERAPEUTICS, INC.(NASDAQ : IOVA) dropped from Russell Midcap Growth Index
CI
06/24IOVANCE BIOTHERAPEUTICS, INC.(NASDAQ : IOVA) dropped from Russell 2500 Growth Index
CI
More news
News in other languages on IOVANCE BIOTHERAPEUTICS, INC.
06/13Iovance Biotherapeutics, Inc. nomme Wendy L. Dixon au conseil d'administration
06/03Iovance Biotherapeutics augmente vendredi après-midi après l'achat d'actions de la soci..
05/27MISE À JOUR SECTORIELLE : Les actions du secteur de la santé terminent en hausse
05/27Les actions d'Iovance Biotherapeutics chutent après les résultats d'un essai clinique s..
05/27MISE À JOUR SECTORIELLE : Les actions du secteur de la santé progressent vendredi avant le..
More news
Analyst Recommendations on IOVANCE BIOTHERAPEUTICS, INC.
More recommendations
Chart IOVANCE BIOTHERAPEUTICS, INC.
Duration : Period :
Iovance Biotherapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IOVANCE BIOTHERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 11,57 $
Average target price 27,23 $
Spread / Average Target 135%
EPS Revisions
Managers and Directors
Frederick G. Vogt President, CEO, Secretary & General Counsel
Jean-Marc Bellemin CFO & Principal Accounting Officer
Iain David Dukes Chairman
Friedrich Graf Finckenstein Chief Medical Officer
Kristin Lanzi Vice President-Information Technology
Sector and Competitors